rs622342A>C in SLC22A1 is associated with metformin pharmacokinetics and glycemic response
作者: Khaled NajaSaid El ShamiehRajaa Fakhoury
作者单位: 1Department of Biological Sciences, Faculty of Science, Beirut Arab University, Beirut, Lebanon
2Department of Medical Laboratory Technology, Faculty of Health Sciences, Beirut Arab University, Beirut, Lebanon
刊名: Drug Metabolism and Pharmacokinetics, 2020, Vol.35 (1), pp.160-164
来源数据库: Elsevier Journal
DOI: 10.1016/j.dmpk.2019.10.007
关键词: Type 2 diabetes mellitusMetformin pharmacokineticsRs622342A>CSLC22A1
英文摘要: Abstract(#br)Polymorphisms in SLC22A1 lead to variability in metformin clinical efficacy. Sixty-three Lebanese patients with type 2 diabetes who administered metformin, were followed up for six months and genotyped for rs622342A>C. The area under the plasma concentration-time curve and the maximum concentration of metformin was highest in CC patients (P ≤ 0.03). There was a significant difference between groups in the percentage decrease in fasting blood sugar (FBS) and glycated hemoglobin (HbA 1 c). Going into the same direction, rs622342C was associated with decrease in FBS levels after three and six months of treatment (P ≤ 0.02), whereas with HbA 1 c, the decrease was noticed after six months (β = −2.78; P = 0.03). In contrast, the serum levels of lactate and creatinine did not vary...
全文获取路径: Elsevier  (合作)
影响因子:2.071 (2012)

  • metformin 二甲双胍
  • associated 相关的
  • response 响应
  • SLC Secured Logon Coordinator